Literature DB >> 9756948

Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase.

J Kotera1, K Fujishige, H Akatsuka, Y Imai, N Yanaka, K Omori.   

Abstract

After our recent findings that the amino-terminal portion of rat cGMP-binding, cGMP-specific phosphodiesterase (cGB-PDE) differs from those of bovine and human cGB-PDEs, we found two forms of canine cGB-PDE cDNAs (CFPDE5A1 and CFPDE5A2) in canine lung. Each contained a distinct amino-terminal sequence, CFPDE5A1, possessing an amino-terminal portion with sequence similar to those of bovine and human, and CFPDE5A2, having one similar to that of rat. Other portions coding for the cGMP binding domains and the catalytic domain were conserved. Both CFPDE5A1 and CFPDE5A2 transcripts were detected in the cerebellum, hippocampus, retina, lung, heart, spleen, and thoracic artery. CFPDE5A1 transcripts were particularly abundant in the pylorus, whereas CFPDE5A2 transcripts were quite low in this tissue. CFPDE5A1 and CFPDE5A2 expressed in COS-7 cells had cGMP Km values of 2.68 and 1.97 microM, respectively, and both were inhibited by a low concentration of a cGB-PDE inhibitor, Zaprinast. Both CFPDE5A1 and CFPDE5A2 bound cGMP to their allosteric cGMP binding domains, and this cGMP binding was stimulated by 3-isobutyl-1-methylxanthine. Thus, two types of alternative splice variants of canine cGB-PDE have been identified and shown to have similar biological properties in vitro.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756948     DOI: 10.1074/jbc.273.41.26982

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle.

Authors:  K S Murthy
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

Review 2.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

Review 3.  The emerging role for type 5 phosphodiesterase inhibition in heart failure.

Authors:  Gregory D Lewis; Marc J Semigran
Journal:  Curr Heart Fail Rep       Date:  2006-09

Review 4.  Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.

Authors:  Gregory D Lewis; Marc J Semigran
Journal:  Curr Heart Fail Rep       Date:  2004-12

5.  Inhibition of cyclic GMP hydrolysis with zaprinast reduces basal and cyclic AMP-elevated L-type calcium current in guinea-pig ventricular myocytes.

Authors:  Mark T Ziolo; Susanne J Lewandowski; Jacquelyn M Smith; Fred D Romano; Gordon M Wahler
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

6.  Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes.

Authors:  Liliana R V Castro; Ignacio Verde; Dermot M F Cooper; Rodolphe Fischmeister
Journal:  Circulation       Date:  2006-05-01       Impact factor: 29.690

7.  Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes.

Authors:  Honglan Wang; Mark J Kohr; Christopher J Traynham; Mark T Ziolo
Journal:  J Mol Cell Cardiol       Date:  2009-04-01       Impact factor: 5.000

8.  Design of novel β-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors.

Authors:  Dalia S El-Gamil; Nermin S Ahmed; Bernard D Gary; Gary A Piazza; Matthias Engel; Rolf W Hartmann; Ashraf H Abadi
Journal:  Arch Pharm (Weinheim)       Date:  2013-01       Impact factor: 3.751

9.  Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy.

Authors:  C C Watkins; A Sawa; S Jaffrey; S Blackshaw; R K Barrow; S H Snyder; C D Ferris
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.